Performance and Practicality of 16S Nanopore Sequencing for Routine Bacterial Identification in Clinical Samples

This study validates a rapid, cost-effective 16S rRNA nanopore sequencing workflow for routine clinical bacterial identification, demonstrating high concordance with Illumina sequencing while significantly reducing turnaround time and offering a practical solution for decentralized diagnostics of low-diversity samples.

The Gist

Imagine you are a detective trying to solve a mystery inside a patient's body. The mystery? What bacteria are causing an infection?

For decades, the only way to solve this was to take a sample, put it in a petri dish (like a tiny garden), and wait for the bacteria to grow big enough to see. But this method has two big flaws:

1. It's slow: You might have to wait days for the "garden" to grow.
2. It often fails: If the patient already took antibiotics, or if the bacteria are "picky eaters" that refuse to grow in a dish, the detective comes up empty-handed.

In recent years, scientists started using DNA sequencing as a super-powered magnifying glass. Instead of waiting for the bacteria to grow, they read the bacteria's genetic ID card (the 16S gene). This is much faster and works even if the bacteria are dead or hiding.

However, there were two main "detective tools" available, and they had their own pros and cons:

• The "Gold Standard" (Illumina): This is like a high-end, expensive library. It's incredibly accurate and can read millions of books at once, but it takes a long time to set up, costs a fortune, and you usually need a huge crowd of samples to make it worth the price.
• The "New Kid" (Nanopore/ONT): This is like a portable, handheld scanner. It's fast, cheap, and can work on just one or two samples. But, because it's newer, doctors were worried it might make more mistakes or miss the tiny clues compared to the Gold Standard.

The Big Experiment

The authors of this paper (a team of Swiss scientists) decided to put these two tools to the test. They wanted to see if the portable scanner (Nanopore) could do the same job as the high-end library (Illumina) when looking at real patient samples from sterile body parts (like joints and spine biopsies).

They set up a "training camp" with pure bacteria cultures to see how low a concentration each tool could detect. Then, they took 101 real patient samples and ran them through both machines.

What They Found (The Verdict)

1. The Accuracy Race: A Tie
Surprisingly, the portable scanner was just as good as the expensive library.

• The Metaphor: Imagine two people reading a long, complex novel. One uses a high-powered microscope (Illumina), and the other uses a standard flashlight (Nanopore). The scientists found that both readers identified the characters (bacteria species) with almost identical accuracy (over 99.8% correct).
• They both agreed on what was a "real infection" and what was just "dirt on the lens" (contamination) about 93.5% of the time.

2. The Speed and Cost: The Portable Scanner Wins
This is where the Nanopore tool shined.

• Time: The Illumina process took about 50 hours longer to finish a batch of samples. The Nanopore workflow was like a sprint; it got results much faster.
• Cost: For a small batch of 24 samples, the Nanopore cost about $44 per sample, while the Illumina cost about $200 per sample.
• The Metaphor: If you need to send a letter, Illumina is like waiting for a massive cargo ship that only leaves when it's full (cheap per item if full, but slow and expensive if you only have one letter). Nanopore is like a drone delivery: it's slightly more expensive per letter if you send a million, but for just a few letters, it's instant and affordable.

3. The "False Alarm" Problem
Both tools sometimes picked up "noise"—tiny bits of bacteria that weren't actually causing the infection (like skin bacteria that got on the sample by accident).

• The scientists found that both tools made similar mistakes here. However, they learned that if a sample had too many different types of bacteria, it was likely a contamination (a false alarm). If it had just one or two strong types, it was likely a real infection. A human expert (an infectious disease doctor) was needed to make the final call, and both tools gave the doctor equally good information to make that decision.

Why This Matters

This study is a game-changer for hospitals. It proves that you don't need a massive, expensive supercomputer to diagnose infections quickly.

• For the Patient: They get answers faster. If a doctor knows exactly which bacteria is causing the infection within hours instead of days, they can prescribe the right antibiotic immediately, rather than guessing.
• For the Hospital: They can set up these tests in smaller labs or even in remote areas (because the machine is portable), saving money and time.
• For the Future: It opens the door for "decentralized" medicine, where high-tech diagnostics aren't just for big city hospitals, but can be used right where the patient is.

The Bottom Line

The scientists concluded that the Nanopore technology is ready for prime time. It's fast, cheap, and accurate enough to replace the old, slow methods for many types of infections. It's like upgrading from a flip phone to a smartphone: it does the same core job (making calls/identifying bacteria), but it does it faster, cheaper, and with more features for the modern world.

Technical Summary

1. Problem Statement

Accurate and timely identification of bacterial pathogens in clinical samples, particularly those with low bacterial biomass (e.g., sterile body sites), is critical for effective treatment. However, traditional culture-based methods often fail due to prior antibiotic exposure or fastidious growth requirements. While 16S rRNA gene sequencing offers a culture-independent alternative, current technologies face limitations:

• Sanger Sequencing: Cannot resolve polymicrobial infections.
• Illumina (Short-Read NGS): Offers high precision but suffers from long turnaround times, high hardware costs, and a requirement for large batch sizes to be cost-effective, making it less suitable for rapid, on-demand clinical diagnostics.
• Oxford Nanopore Technologies (ONT): Promising due to speed and portability, but its clinical adoption is hindered by a lack of standardized, validated protocols and a scarcity of large-scale comparative data against established NGS methods.

2. Methodology

The study developed and benchmarked a rapid, cost-effective 16S rRNA diagnostic workflow using ONT against an Illumina NGS workflow.

• Sample Cohort:
  • Verification: Dilution series of pure and mixed E. coli and S. aureus cultures (down to ~30 CFU/ml) to test detection limits.
  • Clinical Application: 101 prospective clinical samples from normally sterile body sites (predominantly joint and spine biopsies) collected over 1.5 years.
• Wet Lab Protocol:
  • Extraction & Amplification: Used the Micro-Dx kit (Molzym), an IVD-certified, DNA-free reagent system for automated microbial DNA enrichment and real-time 16S PCR targeting the V3-V4 region.
  • Sequencing:
    • ONT: Performed on GridION X5 with R10.4.1 flow cells using the SQK-NBD114.24 kit. Libraries were pooled (1–20 samples) and sequenced for up to 1 hour.
    • Illumina: Performed on MiSeq (v2 reagents, 2x250 bp) with pooled libraries (68–76 samples).
  • Controls: Extensive negative controls (extraction, PCR, library prep) were included to monitor contamination.
• Bioinformatics:
  • ONT: Analyzed using the LORCAN pipeline (trimming, filtering, subsampling to 9,000 reads, consensus generation, and BLAST mapping).
  • Illumina: Processed using DADA2 (denoising, ASV generation, filtering to 390–450 bp, BLAST mapping).
  • Thresholds: Species required a minimum of 100 reads to be reported.
• Validation:
  • Results were compared against culture findings.
  • A retrospective clinical review by an experienced infectiologist assessed the plausibility of detected pathogens based on patient history, distinguishing true infections from contaminants.

3. Key Contributions

• Standardized Clinical Workflow: Established a validated, IVD-certified pipeline for 16S Nanopore sequencing suitable for routine diagnostics.
• Direct Large-Scale Comparison: Provided one of the first direct, head-to-head comparisons of ONT and Illumina on a large cohort (101 samples) of low-biomass clinical specimens.
• Contamination Management: Demonstrated the efficacy of DNA-free reagents and specific read-count thresholds (100 reads) in minimizing false positives from reagent contamination.
• Cost/Time Analysis: Quantified the operational advantages of ONT for small-batch, decentralized clinical settings.

4. Key Results

• Analytical Sensitivity:
  • Both platforms successfully detected species at high concentrations.
  • At low concentrations (<310 CFU/ml), Illumina showed slightly higher sensitivity, detecting S. aureus in 2/3 replicates at 80 CFU/ml where ONT failed. However, both methods struggled below this threshold.
  • In polymicrobial mixtures, both methods accurately identified species ratios, though Gram-negative (E. coli) abundance was slightly overestimated due to easier lysis.
• Clinical Concordance:
  • Species Overlap: High agreement between platforms. 93.5% weighted species overlap and a Cohen's kappa of 0.81 upon clinical review.
  • Accuracy: Consensus sequence accuracy was nearly identical: 99.9% for ONT vs. 99.8% for Illumina.
  • Contamination: Both methods detected similar levels of contaminants in clinical samples. Illumina showed slightly more false positives in dilution series, but this did not translate to significant differences in clinical sample interpretation.
• Clinical Plausibility:
  • 76.2% of samples were classified as having a "likely pathogen" by both methods after clinical review.
  • There was zero discordance between ONT and Illumina regarding the classification of a sample as "pathogen" vs. "contamination."
  • The Positive Predictive Value (PPV) relative to culture was low (0.08%) due to the high rate of culture-negative samples, but rose to 76.2% when using a composite reference (culture + clinical review).
• Efficiency & Cost:
  • Turnaround Time: The ONT workflow was significantly faster, requiring ~50 hours less total processing time (Library Prep: 5h vs 7h; Sequencing: 2h vs 43h).
  • Cost: ONT consumables cost ~35 CHF ($44) per sample (batch of 24) vs. 155 CHF ($200) for Illumina. ONT is more cost-effective for small batches as flow cells can be reused, whereas Illumina cartridges are single-use.

5. Significance

This study provides strong evidence that 16S Nanopore sequencing is a feasible, high-resolution, and time-efficient alternative to established Illumina NGS methods for routine clinical diagnostics.

• Clinical Impact: It enables rapid, decentralized identification of pathogens in low-biomass samples (e.g., prosthetic joint infections) where culture fails, potentially guiding faster and more appropriate antibiotic therapy.
• Operational Viability: The workflow proves that ONT is not only scientifically accurate but also economically and logistically superior for on-demand, small-batch clinical testing.
• Future Outlook: While the V3-V4 region limits some taxonomic resolution (e.g., distinguishing E. coli from Shigella), the study advocates for the integration of ONT into standard care, with future improvements expected from full-length 16S IVD kits and refined bioinformatic filtering for low-abundance reads.